Diagnosis Biotech was founded in 2020 in response to the COVID-19 pandemic to find ways to enable mass testing for broad SARS-CoV-2 screening.
We developed and validated Phone Screen Testing (PoST), a new accurate, low-cost and non-invasive method to test SARS-CoV-2 from the screen of smartphones.
PoST was shown to be as accurate in identifying COVID-19 contagious people as nasopharyngeal sampling.
We are now working on expanding the B2B and B2C COVID-19 testing service from Chile, where PoST was piloted, to LATAM, the UK and USA.
In parallel, we are developing the first PoST machine that will take and analyse samples from phones to identify over 50 pathogens in 10 minutes.
The aim is to generate a broad and distributed network of PoST machines to enable mass testing for epidemiological surveillance of all kinds of infectious diseases.
Company Details
- Employees
- 3
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- from Chile.
Diagnosis Biotech Questions
Diagnosis Biotech's LinkedIn profile is https://www.linkedin.com/company/diagnosis-biotech
Diagnosis Biotech has
3 employees.
View email and phone details for 3
employees at Diagnosis Biotech.
Diagnosis Biotech's industry is
Biotechnology Research
Diagnosis Biotech's top competitors are
British And Irish Orthoptic Journal,
Omiolabs,
Eye2gene,
Inverskin,
Inactive Page. Ucl Institute Of Ophthalmology.,
Andes Biotechnologies S.a.,
Moorfields Ophthalmic Reading Centre & Clinical Ai Lab,
Atacama Astronomical Park,
Biogentech,
The Minimal Magazine.
Diagnosis Biotech's categories are Biotechnology Research
Diagnosis Biotech's founding year is 2020
